Submit a Letter to the Editor for:
Atsushi Suzuki, Satoru Naruse, Motoji Kitagawa, Hiroshi Ishiguro, Toshiyuki Yoshikawa, Shigeru B.H. Ko, Akiko Yamamoto, Hiroyuki Hamada, Tetsuo Hayakawa
J Clin Invest. 2001;
108(5):749
doi:10.1172/JCI12312
Abstract |
Full text
|
PDF
W
e studied the distribution of 5-hydroxytryptamine– (5-HT-) containing cells in the guinea pig pancreas and examined the effects of 5-HT on fluid secretion by interlobular pancreatic ducts. The 5-HT–immunoreactive cells with morphological characteristics of enterochromaffin (EC) cells were scattered throughout the duct system and were enriched in islets of Langerhans. The fluid secretory rate in the isolated interlobular ducts was measured by videomicroscopy. Basolateral applications of 5-HT strongly but reversibly reduced HCO3-dependent, as well as secretin- and acetylcholine- (ACh-) stimulated, fluid secretion, whereas 5-HT applied into the lumen had no such effects. Secretin-stimulated fluid secretion could be inhibited by a 5-HT3 receptor agonist, but not by agonists of the 5-HT1, 5-HT2, or 5-HT4 receptors. Under the stimulation with secretin, 5-HT decreased the intracellular pH (pHi) and reduced the rate of pHi recovery after acid loading with NH4+, suggesting that 5-HT inhibits the intracellular accumulation of HCO3–. The elevation of intraductal pressure in vivo reduced secretin-stimulated fluid secretion, an effect that could be attenuated by a 5-HT3 receptor antagonist. Thus, 5-HT, acting through basolateral 5-HT3 receptors, strongly inhibits spontaneous, secretin-, and ACh-stimulated fluid secretion by guinea pig pancreatic ducts. 5-HT released from pancreatic ductal EC cells on elevation of the intraductal pressure may regulate fluid secretion of neighboring duct cells in a paracrine fashion.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
